Scleroderma, Systemic: Clinical Trials

10 trials for Scleroderma, Systemic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 410Completed 10

Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate
Tofacitinib, Methotrexate - Scleroderma, Systemic
Phase 4CompletedBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh342024-12-212026-03-16
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
Upfront autologous HSCT - Systemic Sclerosis, Systemic Scleroses, Diffuse
Phase 4CompletedUMC Utrecht602020-09-172026-03-24
Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients
Acetylsalicylic acid, Placebo oral capsule - Systemic Sclerosis
Phase 4CompletedFederal University of São Paulo702018-08-282021-12-01
The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis
bosentan - Scleroderma, Systemic
Phase 4CompletedUniversity Medical Center Groningen202015-06-262018-12-13
Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis
Saccharomyces Boulardii Oral Tablet, Metronidazole - Systemic Sclerosis, Small Intestinal Bacterial Overgrowth
Phase 4CompletedCoordinación de Investigación en Salud, Mexico392015-06-012019-07-30
Bosentan in Systemic Sclerosis
Bosentan - Systemic Sclerosis, Digital Ulcers
Phase 4CompletedActelion182011-03-312026-06-03
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
tadalafil and ambrisentan upfront combination therapy - Pulmonary Arterial Hypertension, Systemic Sclerosis
Phase 4CompletedJohns Hopkins University252010-01-012017-09-12
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
Ambrisentan - Systemic Sclerosis, Shortness of Breath
Phase 4CompletedUniversity of California, Los Angeles122009-03-012020-11-02
Pulmonary Artery Remodelling With Bosentan
bosentan - Hypertension, Pulmonary
Phase 4CompletedActelion112006-05-312026-06-03
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Pletal - Raynaud's Disease
Phase 4CompletedOtsuka America Pharmaceutical752001-10-012005-07-19

Narrower conditions

Hypertension, Pulmonary (3)  ·  Scleroderma, Diffuse (3)  ·  Connective Tissue Diseases (2)  ·  Autoimmune Diseases (1)  ·  Dyspnea (1)  ·  Hypertension (1)  ·  Mixed Connective Tissue Disease (1)  ·  Pulmonary Arterial Hypertension (1)  ·  Raynaud Disease (1)  ·  Sclerosis (1)  ·  digital ulcers (1)

Broader conditions

Skin Diseases (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Connective Tissue Diseases (8)  ·  Cardiovascular Diseases (4)  ·  Vascular Diseases (4)  ·  Lung Diseases (3)  ·  Respiratory Tract Diseases (3)  ·  Hypertension (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Embolism and Thrombosis (1)  ·  Immune System Diseases (1)  ·  Livedoid Vasculopathy (1)  ·  Pathologic Processes (1)  ·  Peripheral Vascular Diseases (1)

Interventions

Bosentan (3)  ·  ambrisentan (2)  ·  Aspirin (1)  ·  Cilostazol (1)  ·  Methotrexate (1)  ·  Metronidazole (1)  ·  Tadalafil (1)  ·  tofacitinib (1)

Sponsors

Actelion (2)  ·  Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1)  ·  Coordinación de Investigación en Salud, Mexico (1)  ·  Federal University of São Paulo (1)  ·  Johns Hopkins University (1)  ·  Otsuka America Pharmaceutical (1)  ·  UMC Utrecht (1)  ·  University Medical Center Groningen (1)  ·  University of California, Los Angeles (1)

Countries

Netherlands (3)  ·  United States (3)  ·  Australia (1)  ·  Bangladesh (1)  ·  Brazil (1)  ·  Italy (1)  ·  Mexico (1)  ·  United Kingdom (1)

Top investigators

Andries J Smit, MDPhD (1)  ·  Cristiane Kayser, PhD (1)  ·  David Celermajer, Professor (1)  ·  Dinesh Khanna, MD (1)  ·  Jacob M van Laar, MD PhD (1)  ·  Julia Spierings (1)  ·  Md. Abu Shahin, FCPS, MD (1)  ·  Paul Hassoun, MD (1)  ·  Rajeev Saggar, MD (1)

Results publications

PMID 22777623, PMID 26360334, PMID 29251556, PMID 31549334, PMID 33737437

NIH funding

P50HL084946 (1)